期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 92, 期 4, 页码 437-439出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.125
关键词
-
资金
- National Institutes of Health [UL1 RR029890, UL1 RR029890-03S2, U01 GM074492, U01HL105198-07S1, R24 GM061374]
Although there is increasing evidence to support the implementation of pharmacogenetics in certain clinical scenarios, the adoption of this approach has been limited. The advent of preemptive and inexpensive testing of critical pharmacogenetic variants may overcome barriers to adoption. We describe the design of a customized array built for the personalized-medicine programs of the University of Florida and Stanford University. We selected key variants for the array using the clinical annotations of the Pharmacogenomics Knowledgebase (PharmGKB), and we included variants in drug metabolism and transporter genes along with other pharmacogenetically important variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据